
SCLC Treatment Advances Compound With EGFR- and KRAS-Directed NSCLC Updates at ESMO 2026
Drs Park and Patil discuss DeLLphi-305, MAVERICK, FLAURA2, MARIPOSA, SAFFRON, Krascendo 1 and other lung cancer data from the 2026 ESMO Congress.
In this episode of Oncology Unplugged, Chandler Park, MD, MSc, FACP, of Norton Cancer Institute in Louisville, Kentucky, spoke with Tejas Patil, MD, an assistant professor of medicine and vice head of Clinical Affairs in the Division of Medical Oncology at the University of Colorado School of Medicine and the clinical research director of thoracic oncology at the University of Colorado Cancer Center, about lung cancer advances presented at the 2026 ESMO Congress.
The experts discussed small cell lung cancer (SCLC), highlighting the phase 3 DeLLphi-305 trial (NCT06211036) of maintenance tarlatamab-dlle (Imdelltra) plus durvalumab (Imfinzi) in extensive-stage disease. Dr Patil called it potentially the most important study of the meeting, noting an improved median overall survival with the combination than with durvalumab alone. He noted, however, that any-grade cytokine release syndrome occurred in almost half of patients, and he emphasized that standardized order sets, nursing education, and access to tocilizumab (Actemra) and corticosteroids are key to managing this toxicity. Dr Patil also discussed the phase 3 MAVERICK/SWOG S1827 trial, in which cognitive failure–free survival favored MRI surveillance over prophylactic cranial irradiation in extensive-stage SCLC.
In EGFR-mutant non–small cell lung cancer, Dr Patil said nearly all patients should receive upfront treatment intensification, either with osimertinib (Tagrisso) plus chemotherapy per the phase 3 FLAURA2 trial (NCT04035486) or amivantamab-vmjw (Rybrevant) plus lazertinib (Lazcluze) per the phase 3 MARIPOSA trial (NCT04487080). Additionally, the experts noted that in the phase 3 SAFFRON trial (NCT05261399), osimertinib plus savolitinib yielded a longer median OS vs chemotherapy in patients with MET overexpression or amplification. Dr Patil also noted that divarasib (GDC-6036/RG6330) reduced the risk of progression or death vs sotorasib (Lumakras) or adagrasib (Krazati) in patients with KRAS G12C–mutant disease in the phase 3 Krascendo 1 trial (NCT06497556). He also cautioned against applying the FDA complete response letter for ivonescimab plus chemotherapy to the entire PD-1/VEGF class, noting that OS, a co-primary end point of the phase 3 HARMONi trial (NCT06396065), was not met in the cohort of patients with EGFR-mutant disease.
Related to this article








